ID   5637 subclone 1A6
AC   CVCL_6344
SY   5637 (subclone 1A6); 1A6
DR   CLO; CLO_0001149
DR   ATCC; CRL-2742
DR   cancercelllines; CVCL_6344
DR   Cosmic; 2037945
DR   GEO; GSM136246
DR   GEO; GSM827286
DR   GEO; GSM1374374
DR   LINCS_LDP; LCL-1703
DR   Progenetix; CVCL_6344
DR   Wikidata; Q54582656
RX   Patent=US6114166;
RX   PubMed=20215515;
RX   PubMed=24018021;
RX   PubMed=29732388;
CC   Group: Patented cell line.
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-556.
CC   Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CRL-2742; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): ATCC=CRL-2742
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 9
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 16,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0126 ! 5637
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 28
//
RX   Patent=US6114166;
RA   Welte K., Platzer E., Gabrilove J.L., Mertelsmann R., Moore M.A.S.;
RT   "Human pluripotent hematopoietic colony stimulating factor and cell
RT   line producing same.";
RL   Patent number US6114166, 05-Sep-2000.
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//